These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27892645)

  • 1. Endothelial cell-derived endothelin-1 is involved in abnormal scar formation by dermal fibroblasts through RhoA/Rho-kinase pathway.
    Kiya K; Kubo T; Kawai K; Matsuzaki S; Maeda D; Fujiwara T; Nishibayashi A; Kanazawa S; Yano K; Amano G; Katayama T; Hosokawa K
    Exp Dermatol; 2017 Aug; 26(8):705-712. PubMed ID: 27892645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periostin is induced by IL-4/IL-13 in dermal fibroblasts and promotes RhoA/ROCK pathway-mediated TGF-β1 secretion in abnormal scar formation.
    Maeda D; Kubo T; Kiya K; Kawai K; Matsuzaki S; Kobayashi D; Fujiwara T; Katayama T; Hosokawa K
    J Plast Surg Hand Surg; 2019 Oct; 53(5):288-294. PubMed ID: 31066603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophic and keloid scars fail to progress from the CD34
    Limandjaja GC; Belien JM; Scheper RJ; Niessen FB; Gibbs S
    Br J Dermatol; 2020 Apr; 182(4):974-986. PubMed ID: 31206605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
    Ogawa R; Akaishi S
    Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periostin induces fibroblast proliferation and myofibroblast persistence in hypertrophic scarring.
    Crawford J; Nygard K; Gan BS; O'Gorman DB
    Exp Dermatol; 2015 Feb; 24(2):120-6. PubMed ID: 25421393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of In Vitro Reconstructed Human Normotrophic, Hypertrophic, and Keloid Scar Models.
    Limandjaja GC; van den Broek LJ; Breetveld M; Waaijman T; Monstrey S; de Boer EM; Scheper RJ; Niessen FB; Gibbs S
    Tissue Eng Part C Methods; 2018 Apr; 24(4):242-253. PubMed ID: 29490604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular basis of keloid and hypertrophic scar formation.
    Tuan TL; Nichter LS
    Mol Med Today; 1998 Jan; 4(1):19-24. PubMed ID: 9494966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow derived mesenchymal stem cells inhibit the proliferative and profibrotic phenotype of hypertrophic scar fibroblasts and keloid fibroblasts through paracrine signaling.
    Fang F; Huang RL; Zheng Y; Liu M; Huo R
    J Dermatol Sci; 2016 Aug; 83(2):95-105. PubMed ID: 27211019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.
    Bock O; Yu H; Zitron S; Bayat A; Ferguson MW; Mrowietz U
    Acta Derm Venereol; 2005; 85(3):216-20. PubMed ID: 16040405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exclusive expression of KANK4 promotes myofibroblast mobility in keloid tissues.
    Oishi M; Shinjo K; Takanari K; Muraoka A; Suzuki MM; Kanbe M; Higuchi S; Ebisawa K; Hashikawa K; Kamei Y; Kondo Y
    Sci Rep; 2024 Apr; 14(1):8725. PubMed ID: 38622256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in fibroblast alpha1beta1 integrin collagen receptor expression in keloids and hypertrophic scars.
    Szulgit G; Rudolph R; Wandel A; Tenenhaus M; Panos R; Gardner H
    J Invest Dermatol; 2002 Mar; 118(3):409-15. PubMed ID: 11874478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt Signaling Pathway Proteins in Scar, Hypertrophic Scar, and Keloid: Evidence for a Continuum?
    Chaudet KM; Goyal A; Veprauskas KR; Nazarian RM
    Am J Dermatopathol; 2020 Nov; 42(11):842-847. PubMed ID: 32310858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids.
    Lee HJ; Jang YJ
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29498630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of altered fatty acid in pathological scars and their dermal fibroblasts.
    Yang JX; Li SY; Chen ML; He LR
    Chin J Traumatol; 2022 Jul; 25(4):218-223. PubMed ID: 35478090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis.
    Amadeu T; Braune A; Mandarim-de-Lacerda C; Porto LC; Desmoulière A; Costa A
    Pathol Res Pract; 2003; 199(7):469-73. PubMed ID: 14521263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexose sugars differentially alter collagen gene expression and synthesis in fibroblasts derived from granulation tissue, hypertrophic scar and keloid.
    Kössi J; Vähä-Kreula M; Peltonen J; Risteli J; Laato M
    Arch Dermatol Res; 2004 May; 295(12):521-6. PubMed ID: 15045512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR as a potential therapeutic target for treatment of keloids and excessive scars.
    Ong CT; Khoo YT; Mukhopadhyay A; Do DV; Lim IJ; Aalami O; Phan TT
    Exp Dermatol; 2007 May; 16(5):394-404. PubMed ID: 17437482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Collagen metabolism in hypertrophic and keloid scars].
    Del'vig AA
    Vestn Ross Akad Med Nauk; 1995; (12):41-5. PubMed ID: 8664602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids.
    Sato M
    Acta Derm Venereol; 2006; 86(4):300-7. PubMed ID: 16874413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial-to-mesenchymal transition induced by Wnt 3a in keloid pathogenesis.
    Lee WJ; Park JH; Shin JU; Noh H; Lew DH; Yang WI; Yun CO; Lee KH; Lee JH
    Wound Repair Regen; 2015; 23(3):435-42. PubMed ID: 25845828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.